期刊
ACTA ONCOLOGICA
卷 61, 期 10, 页码 1223-1229出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/0284186X.2022.2101023
关键词
Colon cancer; circulating tumour DNA; cell-free DNA; neoadjuvant treatment
类别
资金
- ESMO
- Fondation Contre le Cancer
This study is the first to investigate circulating tumor DNA (ctDNA) in the neoadjuvant setting of early-stage colon cancer. The results suggest that baseline circulating-free DNA is an independent prognostic factor for disease-free survival (DFS), and changes in circulating-free DNA between baseline and surgery may also be associated with prognosis. Additionally, the detection of ctDNA before surgery was not associated with outcome, but an increase in ctDNA levels between baseline and surgery may indicate worse 5-year DFS.
Background While circulating tumour (ct)DNA is an indicator of minimal residual disease and negative prognostic factor in stage II-III colon cancer, no study has ever analysed the value of this biomarker in colon cancer patients treated with neoadjuvant chemotherapy. We sought to fill this gap by using prospectively collected plasma samples from 80 stage III colon cancer patients, receiving one cycle of neoadjuvant FOLFOX followed by surgery +/- adjuvant FOLFOX in the PePiTA trial. Material and Methods Samples were collected at baseline, 2 weeks and surgery. NPY and WIF1 were selected as universal methylation markers for ctDNA, and analysed with ddPCR technology. ROC curves were applied for cut-off points, and outcome measures included 5-year disease-free survival (DFS) and 6-year overall survival (OS). Results After a median follow-up of 52.5 months, baseline circulating-free (cf) DNA was an independent prognostic factor for DFS (HR 3.35, 95% CI: 1.15-9.77, p = .03), and a trend towards a similar association was observed for relative cfDNA changes between baseline and surgery (HR 2.57, 95% CI: 0.94-7.05, p = .07). Among 60 ctDNA assessable patients, 25 (42%) had detectable ctDNA at baseline. While detection of ctDNA at any pre-operative timepoint was not associated with outcome, patients with ctDNA increase (change of the worst trending methylation marker >= 11%, or mean ctDNA change of NPY and WIF1 >= 0%) between baseline and surgery showed a trend towards worse 5-year DFS (HR 3.66, 95% CI: 0.81-16.44, p = .09). Conclusion This is the first study of ctDNA in the neoadjuvant setting of early-stage colon cancer. Results are hypothesis-generating and should be confirmed in larger series.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据